Strategy that delivers measurable outcomes.

The Challenge

A MedTech company had a proven non-invasive transcutaneous monitoring technology for continuously tracking pCO2, pO2, and SpO2 in premature babies and high-acuity patients, eliminating the need for painful, invasive blood gas draws. The clinical case was well established in the NICU, sleep labs, and respiratory departments. The opportunity ahead was significant: acute care units and the homecare market were largely untapped, but required distinct strategies, new clinical evidence, and new commercial partnerships to unlock.

Our Approach

The Outcome

The ICU and ED expansion delivered a 37% increase in qualified leads in the first year, driven by targeted campaigns and KOL-supported clinical validation. The homecare programme generated 50% growth in homecare monitoring revenue, reaching $1.5M in year one. The work established the technology as a credible solution well beyond the NICU and created a replicable commercial model for continued market expansion.

The Challenge

A women's health MedTech company had a genuinely revolutionary device: a suction-based alternative to the 135-year-old instrument used in IUD insertions and gynecological procedures. Clinical data were strong, the need for a gentler patient experience was becoming urgent, and a broader conversation around pain in gynecology was just beginning to take hold in the US. But the brand and the innovation were unknown. No audience, no community, no voice in the conversation. The business model was primarily B2B, and women had never been given the chance to know this innovation existed or to ask for it.

Our Approach

We built the US brand presence from the ground up around one core belief: pain in gynecological care had been ignored for too long, and women deserved to know something better existed. The strategy combined emotional storytelling with clinical credibility, patient voices with physician champions, and a social presence designed to educate and activate. Thought leadership and media placements positioned the brand within the broader FemTech conversation. Physician champions whose organic content extended reach far beyond owned channels became a cornerstone of the strategy.

The Outcome

A single social media post went viral: 3.5 million views in 48 hours, with over 2,000 comments from women demanding access to the device. That signal reshaped the strategic conversation. A B2B-only model could no longer capture the full opportunity, and a direct-to-consumer dimension was built on the back of that demand. National media followed, with coverage in The New York Times, Forbes, CBS Mornings, and USA Today. In 2026, organic physician content reignited the conversation with over 6,000 comments, confirming the community had a life of its own and that market traction was real, sustained, and growing.